• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Arlington Capital buys Avalign

Arlington Capital buys Avalign

August 17, 2015 By Fink Densford

Arlington Capital buys AvalignArlington Capital said today that it acquired medical device maker Avalign Technologies in a sale financed by CIT Healthcare.

Forest, Ill.-based Avalign manufactures implants, specialty instrumentation, cutting tools, cases and trays for the orthopedic medical device and specialty surgical markets.

“We are extremely pleased to be partnering with Arlington Capital. Avalign is committed to improving patient outcomes by providing best-in-class medical devices through our industry leading end-to-end capabilities. We believe that Arlington Capital, which has deep expertise and an impressive track record in healthcare and precision manufacturing, is the ideal partner to help us achieve our goals. We would also like to thank RoundTable Healthcare Partners for all of their support and partnership to date,” Avalign CEO Forrest Whittaker said in a press release.

“Avalign is an established leader in the large and growing orthopedic precision manufacturing market. Recognized across the industry for its superior engineering and manufacturing capabilities, Avalign provides significant value to its OEM partners through design improvement, speed to market acceleration and cost reductions. We look forward to partnering with the highly talented Avalign management team to support the company through its next phase of growth,” Arlington Capital partner Matt Altman said in prepared remarks.

CIT Healthcare said they served as joint lead arranger for a $135 million secured credit facility to support the deal.

Arlington Capital bought Avalign from RoundTable Healthcare partners, who are invested in a handful of medical device companies, such as Argon Medical.

“We’re pleased to lead this transaction as we put our knowledge and extensive expertise in the medical device manufacturing space to work for Arlington. Avalign is focused on serving the growing $36 billion global orthopedic market, serving OEM customers who supply highly demanded technologies to the industry’s fastest growing end-markets, including extremities, sports medicine and trauma,” CIT Healthcare managing director William Douglass said in a prepared statement.

Filed Under: Business/Financial News, Mergers & Acquisitions Tagged With: Arlington Capital Partners, Avalign Technologies, RoundTable Healthcare Partners

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy